Ube and Galts Pharma enter licensing agreement for UD-051

July 15, 2025

Ube Corp. and Galts Pharma Co. Ltd., a venture company from Kumamoto University, have signed an agreement giving Galts exclusive worldwide rights to develop, manufacture and market UD-051 (GP-051), a compound discovered through joint research by Ube and Kumamoto University.

BioWorld Science Deals and M&A License Nephrology

Today's news in brief

BioWorld

BioWorld briefs for Nov. 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 14, 2025.

Deal handshake with coin, chart background

ABL Bio’s Grabody lands second $2.6B deal, this time with Lilly

BioWorld

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform....

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...